Recognizing the Disruptive Potential of Cancer Immunotherapy

This article from MDB Communications discusses ten cancer vaccine programs in mid- and late-stage development with important catalysts expected during the balance of 2013 and into 2014. The article also highlights how several of these newer products seem to work better and address the limitations of prior cancer vaccine approaches. The 11-page report is available electronically as a PDF file.  To view/download a complimentary copy of the report, please click here.

Leave a Reply

Your email address will not be published. Required fields are marked *